Hepatocellular carcinoma also frequently shows secondary resistance associated with sorafenib administration, because of the activation of compensatory pathways, such as the PI3K/Akt and JAK-STAT pathways, EMT, and tumor hypoxia [21]. This evidence concerns the gene AKT1 and neoplasm.